Roivant and Priovant report 62% steroid-free disease control with brepocitinib in uveitis trials
Roivant's brepocitinib succeeds in two Phase 3 uveitis trials, improving steroid-free disease control. Explore the results and FDA plans.
Pharma & Biotech
Pharma & Biotech
Why Pulmovant’s PHocus study design matters for regulatory confidence in pulmonary hypertension associated with interstitial lung disease
Pulmovant completes PHocus enrollment for mosliciguat in PH-ILD. Find out what this milestone really means ahead of 2026 clinical data.